BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853. [PMID: 15138212 DOI: 10.1136/gut.2003.018515] [Cited by in Crossref: 206] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
Number Citing Articles
1 Askling J, Brandt L, Lapidus A, Karlén P, Björkholm M, Löfberg R, Ekbom A. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut. 2005;54:617-622. [PMID: 15831904 DOI: 10.1136/gut.2004.051771] [Cited by in Crossref: 148] [Cited by in F6Publishing: 134] [Article Influence: 8.7] [Reference Citation Analysis]
2 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
3 Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628-1640. [PMID: 19664627 DOI: 10.1053/j.gastro.2009.07.062] [Cited by in Crossref: 361] [Cited by in F6Publishing: 331] [Article Influence: 27.8] [Reference Citation Analysis]
4 Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Dig Dis Sci. 2015;60:951-956. [PMID: 25326115 DOI: 10.1007/s10620-014-3392-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
5 Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009;23:348-52. [PMID: 19440565 DOI: 10.1155/2009/180840] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
6 Bodro M, Paterson DL. Listeriosis in patients receiving biologic therapies. Eur J Clin Microbiol Infect Dis 2013;32:1225-30. [DOI: 10.1007/s10096-013-1873-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
7 Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010;31:553-60. [PMID: 20002026 DOI: 10.1111/j.1365-2036.2009.04206.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
8 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK, Avlund S, Olesen TB, Hoffmann HJ, Nexø BA, Sode J, Vogel U, Andersen V. Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. Pharmacogenomics J 2018;18:87-97. [PMID: 28139755 DOI: 10.1038/tpj.2016.84] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
9 Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006;20:757-790. [PMID: 16979537 DOI: 10.1016/j.berh.2006.06.002] [Cited by in Crossref: 153] [Cited by in F6Publishing: 132] [Article Influence: 10.2] [Reference Citation Analysis]
10 Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. [PMID: 15940615 DOI: 10.1053/j.gastro.2005.03.003] [Cited by in Crossref: 734] [Cited by in F6Publishing: 651] [Article Influence: 43.2] [Reference Citation Analysis]
11 Jones J, Panaccione R. Biologic therapy in Crohn's disease: state of the art. Curr Opin Gastroenterol. 2008;24:475-481. [PMID: 18622162 DOI: 10.1097/mog.0b013e3283043596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
12 Jamali M, Raca G, Rubin CM, Anastasi J. γδ Hepatosplenic T-Cell Lymphoma in a Pediatric Patient With Crohn’s Disease on Combined Immunosuppressive and Immunomodulator Therapy: . Pathology Case Reviews 2012;17:101-7. [DOI: 10.1097/pcr.0b013e318258034c] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:937-943. [PMID: 18177449 DOI: 10.1111/j.1572-0241.2007.01718.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 5.2] [Reference Citation Analysis]
14 Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: The price we have to pay?: . Inflammatory Bowel Diseases 2008;14:1019-21. [DOI: 10.1002/ibd.20407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
15 Caprioli F, Daperno M, Bravatà I, Brigido A, Frigerio D, Secchi O, Rispo A. Who are the patients with Crohn's disease unsuitable to receive an anti-TNFα therapy? Results from a survey of Italian physicians and literature review. Eur J Gastroenterol Hepatol 2021;33:1082-90. [PMID: 34213505 DOI: 10.1097/MEG.0000000000002183] [Reference Citation Analysis]
16 Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharmacol Ther 2014;39:459-77. [PMID: 24405149 DOI: 10.1111/apt.12616] [Cited by in Crossref: 97] [Cited by in F6Publishing: 82] [Article Influence: 12.1] [Reference Citation Analysis]
17 Kondamudi PK, Malayandi R, Eaga C, Aggarwal D. Drugs as causative agents and therapeutic agents in inflammatory bowel disease. Acta Pharmaceutica Sinica B 2013;3:289-96. [DOI: 10.1016/j.apsb.2013.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
18 Herrlinger KR, Jewell DP. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2006;24:1403-12. [PMID: 17081161 DOI: 10.1111/j.1365-2036.2006.03147.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
19 Laharie D, Chanteloup E, Chabrun E, Subtil C, Kowo M, El Hanafi K, DE Lédinghen V. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn’s disease primary responders. Aliment Pharmacol Ther. 2009;29:1240-1248. [PMID: 19416134 DOI: 10.1111/j.1365-2036.2009.03997.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
20 Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 2006;5:9-16. [PMID: 16370952 DOI: 10.1517/14740338.5.1.9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
21 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
22 Nyboe Andersen N, Pasternak B, Friis-Møller N, Andersson M, Jess T. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015;350:h2809. [PMID: 26048617 DOI: 10.1136/bmj.h2809] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 8.1] [Reference Citation Analysis]
23 Moradov D, Shifrin H, Harel E, Nadler-Milbauer M, Weinstock M, Srebnik M, Rubinstein A. The anti-inflammatory activity of a novel fused-cyclopentenone phosphonate and its potential in the local treatment of experimental colitis. Gastroenterol Res Pract 2015;2015:939483. [PMID: 25949237 DOI: 10.1155/2015/939483] [Reference Citation Analysis]
24 Travis SP, Stange EF, Lémann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 Suppl 1:i16-35. [PMID: 16481629 DOI: 10.1136/gut.2005.081950b] [Cited by in Crossref: 423] [Cited by in F6Publishing: 365] [Article Influence: 26.4] [Reference Citation Analysis]
25 Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012;107:1693-1701. [PMID: 22945286 DOI: 10.1038/ajg.2012.298] [Cited by in Crossref: 182] [Cited by in F6Publishing: 157] [Article Influence: 18.2] [Reference Citation Analysis]
26 Val JHD. Old-age inflammatory bowel disease onset: A different problem? World J Gastroenterol 2011; 17(22): 2734-2739 [PMID: 21734781 DOI: 10.3748/wjg.v17.i22.2734] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
27 Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig Liver Dis 2005;37:973-9. [PMID: 16169305 DOI: 10.1016/j.dld.2005.07.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
28 Harel E, Rubinstein A, Chen W, Breuer E, Tirosh B. Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells. Bioorganic & Medicinal Chemistry Letters 2010;20:6518-23. [DOI: 10.1016/j.bmcl.2010.09.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
29 Veerappan SG, Kennedy M, O'Morain CA, Ryan BM. Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis. Eur J Gastroenterol Hepatol 2008;20:588-9. [PMID: 18467922 DOI: 10.1097/MEG.0b013e3282f376ac] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
30 Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
31 Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94:115-133. [PMID: 19944801 DOI: 10.1016/j.mcna.2009.08.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
32 Llanos-Chea A, Shapiro JM, Winter RW, Jerger L, Menz T, Gibson M, Friedmann AM, Treaba D, Papamichael K, Cheifetz AS, Friedman S, Hamilton MJ, Winter HS. Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. Dig Dis Sci 2021. [PMID: 33595782 DOI: 10.1007/s10620-021-06884-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Suzuki T, Iwamoto K, Nozaki R, Saiki Y, Tanaka M, Fukunaga M, Yamada K. Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report. BMC Surg 2021;21:50. [PMID: 33478454 DOI: 10.1186/s12893-021-01060-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Afif W, Loftus EV. Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 2009;38:691-709. [DOI: 10.1016/j.gtc.2009.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
35 Jess T, Gamborg M, Munkholm P, Sørensen TI. Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol. 2007;102:609-617. [PMID: 17156150 DOI: 10.1111/j.1572-0241.2006.01000.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 6.7] [Reference Citation Analysis]
36 Ikeuchi H, Uchino M, Matsuoka H, Bando T, Hirata A, Takesue Y, Tomita N, Matsumoto T. Prognosis following emergency surgery for ulcerative colitis in elderly patients. Surg Today 2014;44:39-43. [PMID: 23553422 DOI: 10.1007/s00595-013-0563-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
37 Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:657-660. [PMID: 15472531 DOI: 10.1097/00054725-200409000-00025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
38 Armuzzi A, Gionchetti P, Daperno M, Danese S, Orlando A, Lia Scribano M, Vecchi M, Rizzello F; GIVI (Gruppo Italiano su Vedolizumab nelle IBD) Group. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Dig Liver Dis. 2016;48:360-370. [PMID: 26821929 DOI: 10.1016/j.dld.2015.12.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
39 Søgaard KK, Cronin-Fenton DP, Pedersen L, Sørensen HT, Lash TL. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2008;14:519-525. [PMID: 18069672 DOI: 10.1002/ibd.20341] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
40 Zhang T, Lin QY, Fei JX, Zhang Y, Lin MY, Jiang SH, Wang P, Chen Y. Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease. Sci Rep 2016;6:29791. [PMID: 27417996 DOI: 10.1038/srep29791] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
41 Jahnsen J, Detlie TE, Vatn S, Ricanek P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:45-52. [PMID: 26395534 DOI: 10.1586/17474124.2015.1091308] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
42 Ruocco E, Cuomo A, Salerno R, Ruocco V, Romano M, Baroni A. Crohn’s disease and its mucocutaneous involvement. Skinmed. 2007;6:179-185. [PMID: 17618178 DOI: 10.1111/j.1540-9740.2007.05907.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
43 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
44 Gregory MH, McKinnon A, Stwalley D, Hippensteel KJ, Loftus EV Jr, Ciorba MA, Olsen MA, Deepak P. Anti-Tumour Necrosis Factor Therapy for Inflammatory Bowel Diseases Do Not Impact Serious Infections after Arthroplasty. J Crohns Colitis 2019;13:182-8. [PMID: 30256926 DOI: 10.1093/ecco-jcc/jjy148] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
45 Zamvar V, Sugarman ID, Tawfik RF, Macmullen-Price J, Puntis JW. Posterior reversible encephalopathy syndrome following infliximab infusion. J Pediatr Gastroenterol Nutr 2009;48:102-5. [PMID: 19172132 DOI: 10.1097/MPG.0b013e31818aedb4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
46 Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008;40:821-826. [PMID: 18472316 DOI: 10.1016/j.dld.2008.03.014] [Cited by in Crossref: 115] [Cited by in F6Publishing: 105] [Article Influence: 8.2] [Reference Citation Analysis]
47 Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull M. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2005;28:126-34. [DOI: 10.1157/13072012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
48 Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005;22:1107-13. [PMID: 16305724 DOI: 10.1111/j.1365-2036.2005.02670.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
49 Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opinion on Drug Safety 2007;6:479-85. [DOI: 10.1517/14740338.6.5.479] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
50 Ye BD. [Inflammatory bowel disease and lymphoproliferative disorders]. Korean J Gastroenterol 2011;58:171-7. [PMID: 22042416 DOI: 10.4166/kjg.2011.58.4.171] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
51 Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy 2006;6:401-8. [DOI: 10.1517/14712598.6.4.401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
52 Everett SM, Hamlin PJ. Evidence-based use of anti-TNFα therapy in Crohn's disease; where are we in 2011? Frontline Gastroenterol 2011;2:144-50. [PMID: 28839599 DOI: 10.1136/fg.2010.003566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
53 Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A; GETAID OBSERV-IBD study group. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2018;47:485-493. [PMID: 29250803 DOI: 10.1111/apt.14419] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 11.6] [Reference Citation Analysis]
54 Leedham SJ, Jankowski JA, Wright NA, Tomlinson IPM. Genetics of inflammatory bowel disease and associated cancers. Curr colorectal cancer rep 2006;2:191-9. [DOI: 10.1007/s11888-006-0022-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Travis S. Is IBD different in the elderly? Inflamm Bowel Dis. 2008;14 Suppl 2:S12-S13. [PMID: 18816682 DOI: 10.1002/ibd.20605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
56 Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Sociale O, Papa A, De Vitis I, Rapaccini GL, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis. 2013;19:1065-1072. [PMID: 23448790 DOI: 10.1097/mib.0b013e3182802909] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 5.9] [Reference Citation Analysis]
57 Schluender SJ, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, Targan SR, Fleshner PR. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747-1753. [PMID: 17704969 DOI: 10.1007/s10350-007-9008-3] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
58 Jewell DP, Satsangi J, Lobo A, Probert C, Forbes A, Ghosh S, Shaffer J, Frenz M, Drummond H, Troy G, Turner S, Younge L, Evans L, Moosa M, Rodgers-Gray B, Buchan S. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005;17:1047-52. [PMID: 16148549 DOI: 10.1097/00042737-200510000-00007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
59 Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OS, Munkholm P. Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark: . Inflammatory Bowel Diseases 2007;13:481-9. [DOI: 10.1002/ibd.20036] [Cited by in Crossref: 269] [Cited by in F6Publishing: 249] [Article Influence: 17.9] [Reference Citation Analysis]
60 Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study. Inflammatory Bowel Diseases 2013;19:1384-9. [DOI: 10.1097/mib.0b013e318281325e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
61 Amre D, Amre R, Prakash S. Inflammatory bowel diseases: current treatment strategies and potential for drug delivery using artificial cell microcapsules. Artificial Cells, Cell Engineering and Therapy. Elsevier; 2007. pp. 454-68. [DOI: 10.1533/9781845693077.4.454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
62 Cullen G, Keegan D, Mulcahy HE, O'donoghue DP. A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease. Clinical Gastroenterology and Hepatology 2009;7:323-8. [DOI: 10.1016/j.cgh.2008.10.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
63 Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behçet disease when other therapies fail. J Pediatr Gastroenterol Nutr 2008;46:212-5. [PMID: 18223383 DOI: 10.1097/MPG.0b013e3181346b60] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
64 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis 2021;15:840-59. [PMID: 32915970 DOI: 10.1093/ecco-jcc/jjaa186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol. 2010;25:810-816. [PMID: 20492339 DOI: 10.1111/j.1440-1746.2009.06195.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
67 Bewtra M. Lymphoma in Inflammatory Bowel Disease and Treatment Decisions. American Journal of Gastroenterology 2012;107:964-70. [DOI: 10.1038/ajg.2011.479] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
68 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
69 Bewtra M, Lewis JD. Safety Profile of IBD: Lymphoma Risks. Medical Clinics of North America 2010;94:93-113. [DOI: 10.1016/j.mcna.2009.08.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
71 Hyams JS, Markowitz JF. Can we alter the natural history of Crohn disease in children? J Pediatr Gastroenterol Nutr 2005;40:262-72. [PMID: 15735477 DOI: 10.1097/01.mpg.0000154660.62359.fe] [Cited by in Crossref: 27] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
72 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
73 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
74 Koh SJ, Kim JW, Kim BG, Lee KL, Im JP, Kim JS. Fluoxetine inhibits hyperresponsive lamina propria mononuclear cells and bone marrow-derived dendritic cells, and ameliorates chronic colitis in IL-10-deficient mice. Dig Dis Sci 2015;60:101-8. [PMID: 25146842 DOI: 10.1007/s10620-014-3326-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
75 Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Alimentary Pharmacology & Therapeutics 2009;30:253-64. [DOI: 10.1111/j.1365-2036.2009.04037.x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 131] [Article Influence: 10.8] [Reference Citation Analysis]
76 Khoudari G, Mansoor E, Click B, Alkhayyat M, Saleh MA, Sinh P, Katz J, Cooper GS, Regueiro M. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study. Clinical Gastroenterology and Hepatology 2020. [DOI: 10.1016/j.cgh.2020.10.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
77 Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip J, Bigard M, Peyrin-biroulet L. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Alimentary Pharmacology & Therapeutics 2009;30:854-63. [DOI: 10.1111/j.1365-2036.2009.4097.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
78 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
79 Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22:1671-1677. [PMID: 17845695 DOI: 10.1111/j.1440-1746.2006.04739.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
80 Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh A. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology 2021;10:1877415. [PMID: 33643693 DOI: 10.1080/2162402X.2021.1877415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Reddy JG, Loftus EV. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am. 2006;35:837-855. [PMID: 17129816 DOI: 10.1016/j.gtc.2006.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
82 Sadowski DC, Bernstein CN, Bitton A, Croitoru K, Fedorak RN, Griffiths A; CAG Crohn's Consensus Group. Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol 2009;23:185-202. [PMID: 19319383 DOI: 10.1155/2009/201430] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
83 Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14(3): 378-389 [PMID: 18200660 DOI: 10.3748/wjg.14.378] [Cited by in CrossRef: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
84 Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837-1841. [PMID: 17041753 DOI: 10.1007/s10350-006-0656-5] [Cited by in Crossref: 126] [Cited by in F6Publishing: 95] [Article Influence: 8.4] [Reference Citation Analysis]
85 Bremner A, Beattie R. Recent advances in the medical therapy of Crohn's disease in childhood. Expert Opinion on Pharmacotherapy 2007;8:2553-68. [DOI: 10.1517/14656566.8.15.2553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
86 Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378-389. [PMID: 18200660 DOI: 10.3748/wjg.v14.i3.378] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Parihar V, Maguire S, Shahin A, Ahmed Z, O’sullivan M, Kennedy M, Smyth C, Farrell R. Listeria meningitis complicating a patient with ulcerative colitis on concomitant infliximab and hydrocortisone. Ir J Med Sci 2016;185:965-7. [DOI: 10.1007/s11845-015-1355-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Koutsounas I, Pyleris E, Karantanos P, Barbatzas C. First diagnosis of inflammatory bowel disease in a 91-year-old man. Case Rep Gastroenterol 2012;6:790-6. [PMID: 23341803 DOI: 10.1159/000346467] [Reference Citation Analysis]
89 Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther. 2009;29:1106-1113. [PMID: 19222411 DOI: 10.1111/j.1365-2036.2009.03973.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
90 Bank S, Julsgaard M, Abed OK, Burisch J, Broder Brodersen J, Pedersen NK, Gouliaev A, Ajan R, Nytoft Rasmussen D, Honore Grauslund C, Roug S, Galsgaard J, Sprogøe Høyer Finsen D, Lindby K, Sørensen J, Larsen L, Rohr Andersen M, Brandslund I, Thomassen M, Green A, Bo Bojesen A, Bek Sørensen S, Vogel U, Andersen V; Danish IBD Genetics Working Group. Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease. Aliment Pharmacol Ther 2019;49:890-903. [PMID: 30811631 DOI: 10.1111/apt.15187] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
91 Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn’s disease. Colorectal Dis. 2005;7:164-168. [PMID: 15720356 DOI: 10.1111/j.1463-1318.2004.00749.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
92 Limdi JK, Shaffer JL. How "NICE" were we with infliximab? Inflamm Bowel Dis 2005;11:705-6. [PMID: 15973126 DOI: 10.1097/01.mib.0000169733.88645.da] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Tran S, Hooker RS, Cipher DJ, Reimold A. Patterns of Biologic Agent Use in Older Males with Inflammatory Diseases: An Institution-Focused, Observational Post-Marketing Study. Drugs & Aging 2009;26:607-15. [DOI: 10.2165/11316350-000000000-00000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
94 Kwon JH, Farrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Critical Reviews in Oncology/Hematology 2005;56:169-78. [DOI: 10.1016/j.critrevonc.2005.02.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
95 Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment? Inflamm Bowel Dis. 2007;13:1299-1307. [PMID: 17600819 DOI: 10.1002/ibd.20211] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
96 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 103] [Article Influence: 9.5] [Reference Citation Analysis]
97 Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am 2009;38:669-89. [PMID: 19913208 DOI: 10.1016/j.gtc.2009.07.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
98 Kayton ML. Cancer and pediatric inflammatory bowel disease. Semin Pediatr Surg. 2007;16:205-213. [PMID: 17602977 DOI: 10.1053/j.sempedsurg.2007.04.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
99 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
100 Li Y, Zuo L, Zhu W, Gong J, Zhang W, Gu L, Guo Z, Cao L, Li N, Li J. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn's disease following immunosuppressive therapy. Medicine (Baltimore). 2015;94:e478. [PMID: 25654387 DOI: 10.1097/md.0000000000000478] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
101 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
102 Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.04337253/suppl_5/v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Predictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis. 2007;13:372-379. [PMID: 17206723 DOI: 10.1002/ibd.20024] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
104 Hadithi M, Cazemier M, Meijer GA, Bloemena E, Felt-Bersma RJ, Mulder CJ, Meuwissen SG, Peña AS, Bodegraven AAV. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol 2008; 14(20): 3183-3187 [PMID: 18506923 DOI: 10.3748/wjg.14.3183] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
105 Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006;55:228-33. [PMID: 16120759 DOI: 10.1136/gut.2005.075937] [Cited by in Crossref: 96] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
106 Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P. Infliximab dependency in children with Crohn’s disease. Alimentary Pharmacology & Therapeutics 2009;29:792-9. [DOI: 10.1111/j.1365-2036.2009.03926.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
107 Heraganahally SS, Au V, Kondru S, Edwards S, Bowden JJ, Sajkov D. Pulmonary toxicity associated with infliximab therapy for ulcerative colitis. Intern Med J 2009;39:629-30. [PMID: 19769687 DOI: 10.1111/j.1445-5994.2009.001999.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
108 Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2. [PMID: 15138201 DOI: 10.1136/gut.2003.020552] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
109 Bressler B, Sands BE. Review article: Medical therapy for fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2006;24:1283-1293. [PMID: 17059510 DOI: 10.1111/j.1365-2036.2006.03126.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
110 Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis. Curr Treat Options Gastroenterol. 2007;10:171-177. [PMID: 17547855 DOI: 10.1007/s11938-007-0010-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
111 Thorne K, Alrubaiy L, Akbari A, Samuel DG, Morrison-Rees S, Roberts SE. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review. Eur J Gastroenterol Hepatol 2016;28:369-82. [PMID: 26825217 DOI: 10.1097/MEG.0000000000000568] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
112 Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766. [PMID: 20684009 DOI: 10.1002/ibd.21416] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
113 Schulze HA, Häsler R, Mah N, Lu T, Nikolaus S, Costello CM, Schreiber S. From model cell line to in vivo gene expression: disease-related intestinal gene expression in IBD. Genes Immun 2008;9:240-8. [PMID: 18340362 DOI: 10.1038/gene.2008.11] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
114 Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. Can J Infect Dis Med Microbiol 2005;16:289-92. [PMID: 18159561 DOI: 10.1155/2005/814698] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
115 Kevans D, Keegan D, Mulcahy HE, O'donoghue DP. Infliximab therapy in Crohn's disease: a pragmatic approach? Aliment Pharmacol Ther 2006;24:351-9. [DOI: 10.1111/j.1365-2036.2006.02979.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
116 Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet 2007;46:645-60. [PMID: 17655372 DOI: 10.2165/00003088-200746080-00002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 144] [Article Influence: 11.1] [Reference Citation Analysis]
117 Allen PB, Laing G, Connolly A, O’Neill C. EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem? BMJ Case Rep. 2013;2013:pii: bcr2013200423. [PMID: 24081592 DOI: 10.1136/bcr-2013-200423] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
118 Felley C, Michetti P. Safety of infliximab in patients suffering from inflammatory bowel disease. Digestion 2004;70:1-2. [PMID: 15297772 DOI: 10.1159/000080074] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 de Vries HS, van Oijen MG, de Jong DJ. Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf 2008;31:1135-44. [PMID: 19026030 DOI: 10.2165/0002018-200831120-00009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
120 Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113-120. [PMID: 25075198 DOI: 10.2147/jir.s65979] [Cited by in Crossref: 172] [Cited by in F6Publishing: 83] [Article Influence: 21.5] [Reference Citation Analysis]
121 Manitrala Ramanampamonjy R, Laharie D, Bonnefoy B, Vergniol J, Amouretti M. Méningoencéphalite à Listeria monocytogenes au cours d’un traitement par infliximab d’une maladie de Crohn. Gastroentérologie Clinique et Biologique 2006;30:157-8. [DOI: 10.1016/s0399-8320(06)73138-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Peyrin-biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease: Review: remission rates in IBD. Alimentary Pharmacology & Therapeutics 2011;33:870-9. [DOI: 10.1111/j.1365-2036.2011.04599.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 90] [Article Influence: 9.5] [Reference Citation Analysis]
123 Herrlinger KR, Fellermann K, Stange EF. Tacrolimus--finally! Gut 2006;55:1224-5. [PMID: 16905691 DOI: 10.1136/gut.2006.093302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
124 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
125 Siegel CA, Levy LC, Mackenzie TA, Sands BE. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1-6. [PMID: 17924559 DOI: 10.1002/ibd.20283] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
126 Jess T, Loftus EV, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, Scott Harmsen W, Langholz E, Binder V, Munkholm P. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007;102:829-836. [PMID: 17222314 DOI: 10.1111/j.1572-0241.2007.01070.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 80] [Article Influence: 6.4] [Reference Citation Analysis]
127 Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881. [PMID: 19558997 DOI: 10.1016/j.cgh.2009.01.004] [Cited by in Crossref: 345] [Cited by in F6Publishing: 314] [Article Influence: 26.5] [Reference Citation Analysis]
128 Ordonez ME, Farraye FA, Di Palma JA. Endemic fungal infections in inflammatory bowel disease associated with anti-TNF antibody therapy. Inflamm Bowel Dis 2013;19:2490-500. [PMID: 23694943 DOI: 10.1097/MIB.0b013e31828f1fba] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
129 Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 51-65 [PMID: 26855812 DOI: 10.4292/wjgpt.v7.i1.51] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
130 Stepaniuk P, Bernstein CN, Nugent Z, Singh H. Characterization of inflammatory bowel disease in elderly hospitalized patients in a large central Canadian Health region. Can J Gastroenterol Hepatol 2015;29:274-8. [PMID: 25874650 DOI: 10.1155/2015/724359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
131 Panteris V, Perdiou A, Tsirimpis V, Karamanolis DG. Acute coronary syndrome after infliximab therapy in a patient with Crohn’s disease. World J Gastroenterol 2006; 12(38): 6235-6238 [PMID: 17036404 DOI: 10.3748/wjg.v12.i38.6235] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
132 Allez M. [Practical use of anti-TNF monoclonal antibodies in inflammatory bowel diseases]. Gastroenterol Clin Biol 2008;32:467-77. [PMID: 18448294 DOI: 10.1016/j.gcb.2008.03.002] [Reference Citation Analysis]
133 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
134 Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L, Cochrane CJ, Aitken S, Fennell J, Rogers P. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29:286-297. [PMID: 19132970 DOI: 10.1111/j.1365-2036.2008.03882.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 6.9] [Reference Citation Analysis]
135 Bank S, Andersen PS, Burisch J, Pedersen N, Roug S, Galsgaard J, Turino SY, Brodersen JB, Rashid S, Rasmussen BK. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14:526-534. [PMID: 24776844 DOI: 10.1038/tpj.2014.19] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 9.5] [Reference Citation Analysis]
136 Stepaniuk P, Bernstein CN, Targownik LE, Singh H. Characterization of inflammatory bowel disease in elderly patients: A review of epidemiology, current practices and outcomes of current management strategies. Can J Gastroenterol Hepatol. 2015;29:327-333. [PMID: 26069892 DOI: 10.1155/2015/136960] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
137 Macfarlane S, Steed H, Macfarlane GT. Intestinal bacteria and inflammatory bowel disease. Crit Rev Clin Lab Sci. 2009;46:25-54. [PMID: 19107650 DOI: 10.1080/10408360802485792] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 5.0] [Reference Citation Analysis]
138 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
139 Dohan A, Faraoun S, Barral M, Guerrache Y, Boudiaf M, Dray X, Hoeffel C, Allez M, Farges O, Beaugerie L, Aparicio T, Marteau P, Fishman E, Lucidarme O, Eveno C, Pocard M, Dautry R, Soyer P. Extra-intestinal malignancies in inflammatory bowel diseases: An update with emphasis on MDCT and MR imaging features. Diagnostic and Interventional Imaging 2015;96:871-83. [DOI: 10.1016/j.diii.2015.02.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
140 Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054-1061. [PMID: 16618399 DOI: 10.1053/j.gastro.2006.02.014] [Cited by in Crossref: 271] [Cited by in F6Publishing: 239] [Article Influence: 16.9] [Reference Citation Analysis]
141 Schmidt LA, Lim MS. T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary. J Hematop. 2009;2:121-126. [PMID: 19669196 DOI: 10.1007/s12308-009-0029-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
142 Chow DK, Sung JJ, Tsoi KK, Wong VW, Wu JC, Leong RW, Chan FK. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Aliment Pharmacol Ther. 2009;29:843-854. [PMID: 19154567 DOI: 10.1111/j.1365-2036.2009.03944.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
143 Larsen L, Drewes AM, Broberg MCH, Fallingborg J, Jacobsen BA, Jensen TB, Jess T. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014. Inflamm Bowel Dis 2018;24:433-9. [PMID: 29361095 DOI: 10.1093/ibd/izx038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
144 Loftus EV. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time. Am J Gastroenterol 2005;100:1435-8. [PMID: 15984960 DOI: 10.1111/j.1572-0241.2005.50622_2.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
145 Subramaniam K, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol. 2013;28:24-30. [PMID: 23094824 DOI: 10.1111/jgh.12015] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
146 Riis A, Martinsen TC, Waldum HL, Fossmark R. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease. Scand J Gastroenterol. 2012;47:649-657. [PMID: 22472026 DOI: 10.3109/00365521.2012.672591] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
147 Kelesidis T, Salhotra A, Fleisher J, Uslan DZ. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? J Infect 2010;60:386-96. [PMID: 20176052 DOI: 10.1016/j.jinf.2010.02.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
148 Billioud V, Peyrin-biroulet L. Can elderly people be treated safely with anti-TNF agents?: . Inflammatory Bowel Diseases 2012;18:594-5. [DOI: 10.1002/ibd.21771] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
149 Radin M, Sciascia S, Roccatello D, Cuadrado MJ. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review. BioDrugs. 2017;31:37-49. [PMID: 28035633 DOI: 10.1007/s40259-016-0206-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 5.4] [Reference Citation Analysis]
150 Herfarth H. Infliximab in Crohnʼs disease: TREAT your friend as if he might become an enemy?: . Inflammatory Bowel Diseases 2007;13:933-4. [DOI: 10.1002/ibd.20120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Giagkou E, Saridi M, Albani E, Gaitanis G, Katsanos A, Bechlioulis A, Bacasis AD, Christodoulou DK, Katsanos KH. Dermal Lesions and Skin Cancer in Patients with Inflammatory Bowel Disease Receiving Immunosuppressive Therapy. Asian Pac J Cancer Prev 2018;19:2845-51. [PMID: 30362311 DOI: 10.22034/APJCP.2018.19.10.2845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Chiorean MV, Pokhrel B, Adabala J, Helper DJ, Johnson CS, Juliar B. Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci 2011;56:1489-95. [PMID: 20953706 DOI: 10.1007/s10620-010-1430-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
153 Mahlich J, Matsuoka K, Sruamsiri R. Biologic treatment of Japanese patients with inflammatory bowel disease. BMC Gastroenterol 2018;18:160. [PMID: 30384833 DOI: 10.1186/s12876-018-0892-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Kollepara SS, Chisti MM, Shatavi SV, Jaiyesimi IA. Peripheral T-cell lymphoma in a patient with Crohn's disease. BMJ Case Rep 2013;2013:bcr2013200606. [PMID: 24114599 DOI: 10.1136/bcr-2013-200606] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
155 Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Surgery in the age of biologics. Gastroenterol Rep (Oxf). 2019;7:77-90. [PMID: 30976420 DOI: 10.1093/gastro/goz004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
156 Wang X, Wang G, Wang J, Liu S, Zhou R, Chen L, Wu T, Huang M, Li J, Song L, Xia B. Coagulation state in patients with Crohn’s disease: the effect of infliximab therapy. European Journal of Gastroenterology & Hepatology 2014;26:955-63. [DOI: 10.1097/meg.0000000000000133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
157 Carter MJ, Lobo AJ, Travis SP; IBD Section; British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16. [PMID: 15306569 DOI: 10.1136/gut.2004.043372] [Cited by in Crossref: 700] [Cited by in F6Publishing: 644] [Article Influence: 38.9] [Reference Citation Analysis]
158 Jess T, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, Munkholm P, Sandborn WJ. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. Gut 2006;55:1248-54. [PMID: 16423890 DOI: 10.1136/gut.2005.079350] [Cited by in Crossref: 154] [Cited by in F6Publishing: 137] [Article Influence: 9.6] [Reference Citation Analysis]
159 Regadas FSP, Pinto RA, Murad-regadas SM, Canedo JA, Leal M, Nogueras JJ, Wexner SD. Short-term outcome of infliximab and other medications on patients with inflammatory bowel disease undergoing ileostomy reversal: Medications for ileostomy reversal. Colorectal Disease 2011;13:555-60. [DOI: 10.1111/j.1463-1318.2010.02186.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
160 Donovan M, Lunney K, Carter-Pokras O, Cross RK. Prescribing patterns and awareness of adverse effects of infliximab: a health survey of gastroenterologists. Dig Dis Sci 2007;52:1798-805. [PMID: 17417731 DOI: 10.1007/s10620-006-9269-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
161 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, Langholff W, Sandborn WJ. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis 2018;24:490-501. [PMID: 29462395 DOI: 10.1093/ibd/izx072] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
162 El-hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschlager J, Thorlacius-ussing O, Olaison G. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:662-8. [DOI: 10.3109/00365521.2012.660540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
163 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
164 Balram B, Battat R, Al-Khoury A, D'Aoust J, Afif W, Bitton A, Lakatos PL, Bessissow T. Risk Factors Associated with Clostridium difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Crohns Colitis 2019;13:27-38. [PMID: 30247650 DOI: 10.1093/ecco-jcc/jjy143] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
165 Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther 2012;36:312-23. [PMID: 22725726 DOI: 10.1111/j.1365-2036.2012.05189.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 5.2] [Reference Citation Analysis]
166 Hyman NH. Crohn's disease: drug therapy or surgery? Expert Rev Gastroenterol Hepatol. 2007;1:187-192. [PMID: 19072408 DOI: 10.1586/17474124.1.2.187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
167 Kim JH, Kim JW. Effect of Immunomodulators and Biologic Agents on Malignancy in Patients with Inflammatory Bowel Disease. Korean J Gastroenterol 2017;70:162. [DOI: 10.4166/kjg.2017.70.4.162] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
168 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 88] [Article Influence: 9.4] [Reference Citation Analysis]
169 Bewtra M, Lewis JD. Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:621-31. [PMID: 20594135 DOI: 10.1586/eci.10.36] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
170 Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 2009;3:485-98. [PMID: 20054439 DOI: 10.2147/btt.2009.3755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
171 Kowalski T, Mack HG. Ocular complications of tumour necrosis factor alpha inhibitors. Clin Exp Optom 2020;103:148-54. [PMID: 31077451 DOI: 10.1111/cxo.12904] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
172 Katz S. “Mind the Gap”: An Unmet Need for New Therapy in IBD. Journal of Clinical Gastroenterology 2007;41:799-809. [DOI: 10.1097/mcg.0b013e318033d71d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
173 López San Román A, Van Domselaar M, Rivero M, Redondo C, Arribas R, Rey A. Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab. J Crohns Colitis 2008;2:93-6. [PMID: 21172197 DOI: 10.1016/j.crohns.2007.10.005] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
174 Andersen NN, Caspersen S, Jess T, Munkholm P. Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study. Journal of Crohn's and Colitis 2008;2:304-9. [DOI: 10.1016/j.crohns.2008.04.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
175 Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008;6:1212-1217; quiz 1176. [PMID: 18848503 DOI: 10.1016/j.cgh.2008.05.010] [Cited by in Crossref: 97] [Cited by in F6Publishing: 84] [Article Influence: 6.9] [Reference Citation Analysis]
176 Weatherhead M, Masson S, Bourke SJ, Gunn MC, Burns GP. Interstitial pneumonitis after infliximab therapy for Crohn’s disease. Inflamm Bowel Dis. 2006;12:427-428. [PMID: 16670533 DOI: 10.1097/01.mib.0000219811.54115.aa] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
177 Rajca S, Grondin V, Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, Devos M, Paintaud G, Piver E, Allez M, Mary JY, Sokol H, Colombel JF, Seksik P. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis. 2014;20:978-986. [PMID: 24788220 DOI: 10.1097/mib.0000000000000036] [Cited by in Crossref: 29] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
178 Melmed GY, Spiegel BM, Bressler B, Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG, Kozuch PL. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn’s disease: one size does not fit all. Clin Gastroenterol Hepatol. 2010;8:655-659. [PMID: 20451665 DOI: 10.1016/j.cgh.2010.04.023] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
179 Van Assche G, Vermeire S, Rutgeerts P. Safety issues with biological therapies for inflammatory bowel disease. Curr Opin Gastroenterol 2006;22:370-6. [PMID: 16760752 DOI: 10.1097/01.mog.0000231810.87901.e8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
180 Lewis SN, Brannan L, Guri AJ, Lu P, Hontecillas R, Bassaganya-Riera J, Bevan DR. Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γ. PLoS One 2011;6:e24031. [PMID: 21904603 DOI: 10.1371/journal.pone.0024031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
181 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
182 Brock C, Brock B, Aziz Q, Møller HJ, Pfeiffer Jensen M, Drewes AM, Farmer AD. Transcutaneous cervical vagal nerve stimulation modulates cardiac vagal tone and tumor necrosis factor-alpha. Neurogastroenterol Motil 2017;29. [PMID: 27957782 DOI: 10.1111/nmo.12999] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
183 Duricova D, Pedersen N, Lenicek M, Jakobsen C, Lukas M, Wewer V, Munkholm P. The clinical implication of drug dependency in children and adults with inflammatory bowel disease: A review. Journal of Crohn's and Colitis 2011;5:81-90. [DOI: 10.1016/j.crohns.2010.12.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
184 Cullen G, Vaughn B, Ahmed A, Peppercorn MA, Smith MP, Moss AC, Cheifetz AS. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. Inflamm Bowel Dis 2012;18:691-6. [PMID: 21648022 DOI: 10.1002/ibd.21783] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
185 Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbom A, Sundström C, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Klareskog L, Feltelius N. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20. [PMID: 15843454 DOI: 10.1136/ard.2004.033241] [Cited by in Crossref: 281] [Cited by in F6Publishing: 226] [Article Influence: 16.5] [Reference Citation Analysis]
186 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
187 Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007;50:1754-1760. [PMID: 17899271 DOI: 10.1007/s10350-007-9077-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
188 Manresa MC, Tambuwala MM, Radhakrishnan P, Harnoss JM, Brown E, Cavadas MA, Keogh CE, Cheong A, Barrett KE, Cummins EP, Schneider M, Taylor CT. Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling. [corrected]. Am J Physiol Gastrointest Liver Physiol 2016;311:G1076-90. [PMID: 27789456 DOI: 10.1152/ajpgi.00229.2016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
189 Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
190 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630. [PMID: 16678077 DOI: 10.1016/j.cgh.2006.03.002] [Cited by in Crossref: 633] [Cited by in F6Publishing: 547] [Article Influence: 39.6] [Reference Citation Analysis]
191 Dignass A, Van Assche G, Lindsay J, Lémann M, Söderholm J, Colombel J, Danese S, D'hoore A, Gassull M, Gomollón F, Hommes D, Michetti P, O'morain C, Öresland T, Windsor A, Stange E, Travis S. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. Journal of Crohn's and Colitis 2010;4:28-62. [DOI: 10.1016/j.crohns.2009.12.002] [Cited by in Crossref: 981] [Cited by in F6Publishing: 886] [Article Influence: 81.8] [Reference Citation Analysis]
192 Carbonnel F. Prise en charge d’une rectocolite hémorragique sévère ou corticorésistante. Gastroentérologie Clinique et Biologique 2007;31:398-403. [DOI: 10.1016/s0399-8320(07)89399-7] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
193 Binder V. Clinical epidemiology--how important now? Gut 2005;54:574-5. [PMID: 15831895 DOI: 10.1136/gut.2004.055111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
194 Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs. 2006;66:1431-1439. [PMID: 16906776 DOI: 10.2165/00003495-200666110-00002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
195 Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010;31:92-101. [PMID: 19709098 DOI: 10.1111/j.1365-2036.2009.04130.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 6.7] [Reference Citation Analysis]
196 Cottone M, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30-35. [PMID: 20951835 DOI: 10.1016/j.cgh.2010.09.026] [Cited by in Crossref: 220] [Cited by in F6Publishing: 191] [Article Influence: 18.3] [Reference Citation Analysis]
197 Cucchiara S, Escher JC, Hildebrand H, Amil-dias J, Stronati L, Ruemmele FM. Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies? Journal of Pediatric Gastroenterology & Nutrition 2009;48:257-67. [DOI: 10.1097/mpg.0b013e31818cf555] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]